Efficacy of hepatitis B immunoglobulin in relation to the gene polymorphisms of human leukocyte Fcγ receptor III (CD16) in Chinese liver transplant patients

Chinese Medical Journal

Volumn 120, Issue 18, 2007, Pages 1606-1610

  Wang, Wei Lin ^a   Zhang, Guo Liang ^a   Wu, Li Hua ^a   Yao, Min Ya ^a   Jin, Jing ^a   Jia, Chang Ku ^a   Xie, Hai Yang ^a   Zhou, Lin ^a   Jiang, Zhi Jun ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Fc gamma RIII; Hepatitis B; Immunoglobulin; Polymorphism; Recurrence

Indexed keywords

ADEFOVIR; CD16 ANTIGEN; CYCLOSPORIN; DNA; FC RECEPTOR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ARTICLE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PROGNOSIS; RECURRENCE RISK; RECURRENT VIRUS INFECTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

EID: 35349030395     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200709020-00011     Document Type: Article

References (33)

1. Samuel D, Muller I, Alexander G, Fassati L, Ducot B, Benhamou JR, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
2. Konig V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G, et al. Long-term follow up of hepatitis B virus infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553-559.
3. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333.
4. Steinmuller T, Seehoffer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535.
5. Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 2005; 39: 58-63.
6. Zheng SS, Chen YM, Liang TB, Lu AW, Wang WL, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transplant 2006; 12: 253-258.
7. Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, Schlicht HJ, et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88: 10445-10449.
8. Lanier LL, Yu G, Phillips JH. Analysis of Fc gamma RIII (CD16) membrane expression and association with CD3 zeta and FceRI-g by site-directed mutation. J Immunol 1991; 146: 1571-1576.
9. Ravetch JV, Perussia B. Alternative membrane forms of FcyRIII (CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989; 170: 481-497.
10. Ory PA, Goldstein IM, Kwoh EE, Clarkson SB. Characterization of polymorphic forms of Fc receptor III on human neutrophils. J Clin Invest 1989; 83: 1676-1681.
11. Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM. Sequence of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 1989; 84: 1688-1691.
12. Vance BA, Huizinga TW, Wardwell K, Guyre PM. Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J Immunol 1993; 151: 6429-6439.
13. Hibbs ML, Tolvanen M, Carpen O. Membrane-proximal Ig-like domain of Fc gamma RIII (CD16) contains residues critical for ligand binding. J Immunol 1994; 152: 4466-4474.
14. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of Fcy RIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059-1070.
15. Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, et al. HLA-A31 and HLA-Aw68 restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 1993; 177: 751-762.
16. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150: 4659-4671.
17. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047-1058.
18. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97:1655-1665.
19. Sarzotti M, Robbins EJ, Hoffman PM. Induction of protective CTL responses in newborn mice by murine retrovirus. Science 1996; 271:1726-1728.
20. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
21. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409.
22. Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002; 8: S67-S73.
23. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003, 38: 86-95.
24. Van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14: 215-221.
25. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, et al. Fc gamma receptor mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189: 371-380.
26. Okayama Y, Hagaman DD, Woolhiser M, Metcalfe DD. Further characterization of Fc gammaRII and Fc gammaRIII expression by cultured human mast cells. Int Arch Allergy Immunol 2001; 124: 155-157.
27. Tamm A, Kister A, Nolte KU, Gessner JR, Schmidt RE. The IgG binding site of human Fc gammaRIIIB receptor involves CC' and FG loops of the membrane-proximal domain. J Biol Chem 1996; 271: 3659-3666.
28. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994; 57: 1-124.
29. Ortaldo JR, Mason AT, O'Shea JJ. Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med 1995; 181: 339-344.
30. Azzoni L, Anegon I, Calabretta B, Perussia B. Ligand binding to Fc gamma R induces c-myc-dependent apoptosis in IL-2 stimulated NK cells. J Immunol 1995; 154: 491-499.
31. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc gamma receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996; 156: 2693-2699.
32. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364.
33. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-850.